Things that might lead to dose changes include how bad the deficiency was, if there are nerve symptoms, if theres ongoing trouble absorbing nutrients, and how each patient responds
Utilizing bipolar-at-risk (BAR) criteria at baseline, which include items reflecting genetic risk (first degree relative suffering from bipolar disorder), depressive, cyclothymic, and sub-threshold mania features, investigators prospectively, over a 12-month period, predicted first episodes of mania/hypomania (74)
Nayan (12:37) Gosh, that's a really, really good question, Taylor
Given the human trials in early 2000s showed no adverse events, despite using enormous doses, and the animal data corroborating this, many practitioners feel comfortable prescribing/recommending BPC-157 (I am not making such a recommendation)